Use of parathyroid hormone in hypoparathyroidism
| Autor: | John P. Bilezikian, Natalie E. Cusano, Dinaz Irani, James Sliney, Mishaela R. Rubin |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
endocrine system medicine.medical_specialty Adolescent Hypoparathyroidism Endocrinology Diabetes and Metabolism Population Parathyroid hormone Article Bone remodeling Endocrinology Teriparatide Internal medicine Vitamin D and neurology Humans Medicine Hypercalciuria Vitamin D Child education Aged education.field_of_study business.industry Middle Aged medicine.disease Parathyroid Hormone Calcium Bone Remodeling business hormones hormone substitutes and hormone antagonists Hormone medicine.drug |
| Zdroj: | Journal of Endocrinological Investigation. 36:1121-1127 |
| ISSN: | 1720-8386 0391-4097 |
| DOI: | 10.1007/bf03346763 |
| Popis: | Hypoparathyroidism is a disorder characterized by hypocalcemia, deficient PTH, and abnormal bone remodeling. Standard treatment of hypoparathyroidism consists of oral calcium and vitamin D supplementation. However, maintaining serum calcium levels can be a challenge. In addition, concerns exist regarding hypercalciuria and ectopic calcifications that can be associated with such treatment. Hypoparathyroidism is the only classic endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved treatment. This review focuses on the use of PTH in the treatment of hypoparathyroidism, in the form of teriparatide [PTH(1-34)] and the full-length molecule, PTH(1-84). Studies in hypoparathyroid subjects demonstrate that PTH(1-34) and PTH(1-84) lower or abolish supplemental calcium and vitamin D requirements as well as increase markers of bone turnover. Densitometric and histomorphometric studies in some subjects treated with PTH(1- 34) and PTH(1-84) show an improvement in bone-remodeling dynamics and return of bone metabolism toward normal levels. Given the chronic nature of hypoparathyroidism, and the expectation that PTH will be used for extended periods of time in hypoparathyroidism, further studies are needed to determine the long-term safety of PTH therapy in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink